title: Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats.
abstract: Incretin analogues and inhibitors of the breakdown of endogenous incretins are antidiabetic drugs that increase β-cell proliferation and glucose-stimulated insulin secretion in rodents and humans. Objectives were to test whether exenatide, exenatide extended-release, and sitagliptin can be safely used in cats, to identify the most effective drug, and to test the effects of prolonged exenatide extended-release administration. Three cats each were given exenatide (0.2-2 µg/kg, q12h, subcutaneously, 5 days), exenatide extended-release (40-400 µg/kg, subcutaneously, once), and sitagliptin (1-10 mg/kg, q24h, orally, 5 days). Before and after treatment, glucose, insulin and glucagon areas under the curve (AUC) were assessed by meal response tests (MRT). Exenatide increased insulin AUC by 224%, 258%, 331% and 93%, exenatide extended-release by 127%, 169%, 178% and 95%, and sitagliptin by 32%, 69%, 62%, and 43%, respectively. The tested drugs are safe to use in cats and enhance insulin secretion. Incretin-based therapy may be beneficial in cats with diabetes mellitus.
authors: Clinic for Small Animal Internal Medicine; Vetsuisse Faculty, University of Zurich, Winterthurerstr. 260, 8057 Zurich, Switzerland.
authors: I
authors: I
authors: Padrutt
authors: Institute of Veterinary Physiology; Vetsuisse Faculty, University of Zurich, Winterthurerstr. 260, 8057 Zurich, Switzerland.
authors: T A
authors: TA
authors: Lutz
authors: Clinic for Small Animal Internal Medicine; Vetsuisse Faculty, University of Zurich, Winterthurerstr. 260, 8057 Zurich, Switzerland.
authors: C E
authors: CE
authors: Reusch
authors: Clinic for Small Animal Internal Medicine; Vetsuisse Faculty, University of Zurich, Winterthurerstr. 260, 8057 Zurich, Switzerland; Department of Animal Medicine, Production and Health, University of Padova, viale dell'Università 16, 35020 Legnaro (PD), Italy; Istituto Veterinario di Novara, Strada Provinciale 9, 28060 Granozzo con Monticello (NO), Italy. Electronic address: ezini@vetclinics.uzh.ch.
authors: E
authors: E
authors: Zini
mesh_terms: D000818:Animals; D019540:Area Under Curve; D002415:Cats / Q000378:metabolism*; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives*; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D054795:Incretins / Q000494:pharmacology*; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D010455:Peptides / Q000494:pharmacology*; D000068900:Sitagliptin Phosphate / Q000494:pharmacology*; D014688:Venoms / Q000494:pharmacology*
chemical_list: D054795:Incretins; D007328:Insulin; D010455:Peptides; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide; D005947:Glucose; D000068900:Sitagliptin Phosphate
keywords: Cats; Diabetes mellitus; Exenatide; Incretins; Sitagliptin